Louisa Gueritz

Title: Louisa Gueritz: Innovator in Pharmaceutical Chemistry

Introduction

Louisa Gueritz is a prominent inventor based in London, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit the CFTR channel. With a total of 2 patents, her work is paving the way for advancements in therapeutic applications.

Latest Patents

Gueritz's latest patents include innovative compounds designed to inhibit the CFTR channel. The first patent focuses on tricyclic compounds, providing a compound of formula I or a pharmaceutically acceptable salt thereof, along with its therapeutic uses. The invention also includes a combination of pharmacologically active agents and a pharmaceutical composition. The second patent involves substituted pyrazino[1',2':1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4',5':3,4]pyrrolo[2,1-c][1,4]oxazines, and pyrimido[4',5':3,4]pyrrolo[1,2-d][1,4]oxazepines, again aimed at inhibiting the CFTR channel, along with its therapeutic applications.

Career Highlights

Louisa Gueritz is currently associated with Novartis AG, where she continues to innovate and contribute to the pharmaceutical industry. Her expertise in developing compounds that target specific biological pathways has garnered attention and respect within the scientific community.

Collaborations

Gueritz has collaborated with notable colleagues, including Mahbub Ahmed and Alexander Ashall-Kelly. These partnerships have enhanced her research and contributed to the successful development of her patented inventions.

Conclusion

Louisa Gueritz is a trailblazer in pharmaceutical chemistry, with her innovative patents reflecting her commitment to advancing medical science. Her work continues to inspire future research and development in the field.